"Immunization" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
| Descriptor ID |
D007114
|
| MeSH Number(s) |
E02.095.465.425.400 E05.478.550 N02.421.726.758.310 N06.850.780.200.425 N06.850.780.680.310
|
| Concept/Terms |
Immunization- Immunization
- Immunizations
- Sensitization, Immunologic
- Sensitization, Immunological
- Immunological Sensitization
- Immunological Sensitizations
- Sensitizations, Immunological
- Immunologic Stimulation
- Immunostimulation
- Immunological Stimulation
- Immunological Stimulations
- Stimulation, Immunological
- Stimulations, Immunological
- Immunologic Sensitization
- Stimulation, Immunologic
|
Below are MeSH descriptors whose meaning is more general than "Immunization".
Below are MeSH descriptors whose meaning is more specific than "Immunization".
This graph shows the total number of publications written about "Immunization" by people in this website by year, and whether "Immunization" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 0 | 3 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2021 | 2 | 1 | 3 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunization" by people in Profiles.
-
The characteristics of pre-existing humoral imprint determine efficacy of S.?aureus vaccines and support alternative vaccine approaches. Cell Rep Med. 2024 01 16; 5(1):101360.
-
Use of Updated COVID-19 Vaccines 2023-2024 Formula for Persons Aged =6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2023. MMWR Morb Mortal Wkly Rep. 2023 Oct 20; 72(42):1140-1146.
-
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 25; 72(34):920-925.
-
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022. MMWR Morb Mortal Wkly Rep. 2022 Nov 11; 71(45):1436-1441.
-
Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged =18 years - United States, July 2022. MMWR Morb Mortal Wkly Rep. 2022 Aug 05; 71(31):988-992.
-
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 01; 71(26):859-868.
-
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 12; 70(45):1579-1583.
-
The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1545-1552.
-
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged =16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 24; 70(38):1344-1348.
-
Immunizations, immunology, and autism. Semin Pediatr Neurol. 2004 Sep; 11(3):214-7.